Circulating tumor DNA (ctDNA) has emerged as an important prognostic factor in patients with cancer. Management of early stage NSCLC remains challenging with a high rate of disease recurrence.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 22 Feb 2026.
The item focuses on Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay.
Review the original article for the full source wording and details.